Libo Pharma

Libo Pharma EBIT per Share

The EBIT per Share of Libo Pharma (7888.TWO) as of Nov 5, 2026 is -2.01 TWD. In the previous year, EBIT per Share was -0.69 TWD — a change of 190.29% (lower).

EBIT per Share

-2.01TWD

YoY

190.29%

Last updated:

EBIT per Share of Libo Pharma is 2024 -2.01 TWD. EBIT per Share of Libo Pharma was 2023 -0.69 TWD. It decreases by 190.29% lower compared to the previous year.

The Libo Pharma EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2023
-0.69 TWD
Jan 1, 2024
-2.01 TWD
The Libo Pharma EBIT per Share history
YEAREBIT per ShareYoY
-2.01TWD+190.29%
-0.69TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Libo Pharma Stock analysis

What does Libo Pharma do? Libo Pharma Corp generates revenue through the development and commercialization of immunotherapeutic drugs targeting hematologic malignancies, oncology indications, immune dysregulation disorders, and regenerative medicine. Its lead product candidate LIB-101 is in development for multiple indications including hematopoietic syndrome of acute radiation syndrome (HSARS), cutaneous T-cell lymphoma (CTCL), and diffuse large B-cell lymphoma (DLBCL). The company focuses on modulating biological pathways such as innate immunity, adaptive immunity, and hematopoiesis to enhance anti-tumor effects. The firm targets pharmaceutical companies and research institutions seeking innovative immunotherapeutic solutions. Its lead product LIB-101 is designed to address unmet medical needs in hematologic malignancies and other oncology areas, leveraging a well-defined mechanism of action. Libo Pharma Corp's development pipeline includes multiple indications, positioning it to serve specialized medical markets requiring advanced therapeutic approaches. Libo Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Libo Pharma stock

EBIT per Share of Libo Pharma is -2.01 TWD in 2024.

EBIT per Share of Libo Pharma changed from -0.69 TWD to -2.01 TWD, representing a 190.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Libo Pharma since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Libo Pharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Libo Pharma